Polyrizon Ltd. Stock Price

NasdaqCM:PLRZ Community·US$10.0m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

PLRZ Share Price Performance

US$0.77

-204.23 (-99.62%)

US$0.77

-204.23 (-99.62%)

US$0.77

Fri, 14 Nov 25

Share Pricen/a

PLRZ Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

0 Rewards

View Full Analysis

Polyrizon Ltd. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.098
: 0%
: 0%
: 0%

View Full Analysis

About PLRZ

Founded: 2005
Employees: 4
CEO: Tomer Izraeli
WebsiteView website: www.polyrizon-biotech.com

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.